Transave

Monmouth Junction, United States Founded: 1997 • Age: 29 yrs Acquired By Insmed
Developer of inhaled pharmaceuticals for the site-specific treatment of serious lung infections
Request Access
Report Incorrect Data
Annual revenue - Latest available
Total funding $13.0M 3 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Transave

Transave is a company based in Monmouth Junction (United States) founded in 1997 was acquired by Insmed in December 2010. Transave has raised $13.04 million across 3 funding rounds from investors including Insmed. Transave operates in a competitive market with competitors including MannKind Corp, aTyr Pharma, ReCode Therapeutics, Impel NeuroPharma and Sirnaomics, among others.

  • Headquarter Monmouth Junction, United States
  • Sectors
    Technology
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Transave Inc
Operational Areas
Technology → Quantum & Emerging Technologies → →
Healthcare → Pharmaceuticals & Therapeutics → →
Healthcare → Healthcare Products & Supplies → →
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $13.04 M (USD)

    in 3 rounds

  • Latest Funding Round
    $2 M (USD), Series A

    Sep 28, 2010

  • Investors
    Insmed
  • Employee Count
    Employee Count
  • Acquired by
    Insmed

    (Dec 02, 2010)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Transave

Transave has successfully raised a total of $13.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2 million completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series A — $2.0M
  • First Round

    (13 Nov 2009)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2010 Amount Series A - Transave Valuation

investors
Jun, 2010 Amount Series A - Transave Valuation

investors
Nov, 2009 Amount Series A - Transave Valuation

investors

Investors in Transave

Transave has secured backing from 1 investor. Prominent investors backing the company include Insmed.

All
Investor Description Founded Year Domain Location
Insmed
Developer of small molecule inhibitors for rare lung diseases
Founded Year Domain Location

Investments & Acquisitions by Transave

Investments

Financial Statements - Transave

Transave Comparisons

+
Add Comparison
Available on Premium

Competitors of Transave

Transave operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, aTyr Pharma, ReCode Therapeutics, Impel NeuroPharma and Sirnaomics, among others.

Company Name Domain Founded year HQ Location Description
MannKind Corp
domain founded_year HQ Location
Developer of small-molecule drugs
aTyr Pharma
domain founded_year HQ Location
Protein biologics are developed for treating rare diseases.
ReCode Therapeutics
domain founded_year HQ Location
Precision medicines for lung-related diseases are developed.
Impel NeuroPharma
domain founded_year HQ Location
Intranasal delivery technology for CNS diseases is developed.
Sirnaomics
domain founded_year HQ Location
RNA-based therapeutics for cancer and fibrosis are developed.
Alexza
domain founded_year HQ Location
Developer of products for the treatment of acute and intermittent conditions

Latest news on Transave

Frequently Asked Questions about Transave

Transave was founded in 1997 and raised its 1st funding round 12 years after it was founded.

Transave is headquartered in Monmouth Junction, United States. It is registered at Monmouth Junction, New Jersey, United States.

Transave is a funded company, having raised a total of $13.04M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5.54M, raised on Nov 13, 2009.

Transave was founded in 1997 in Monmouth Junction, United States, within the biotechnology sector. Inhaled pharmaceuticals are developed by the company for targeted treatment of serious lung infections. The lead product, ARIKACE (liposomal amikacin for inhalation), is being advanced for cystic fibrosis patients facing Pseudomonas infections and those due to non-tuberculous Mycobacteria. Operations focus on respiratory therapeutics, with development centered in the U.S.

Transave's top competitors include MannKind Corp, Sirnaomics and Arcturus Therapeutics.

Transave has 1 investor. Key investors include Insmed.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available